Vosevi contains medications from three HCV antiviral classes. When a triple DAA [direct acting antiviral] works for patients who have suffered treatment failure, a dual therapy with sofosbuvir and velpatasvir works for all genotype 1 patients, and more effectively. This combination works best for the patients who have taken some treatments before and are suffering from compensated or severe cirrhosis. Vosevi is approved by the FDA for the treatment of adults with chronic HCV.